15 research outputs found
Microglia modulates hippocampal synaptic transmission and sleep duration along the light/dark cycle
Microglia, the brain's resident macrophages, actively contributes to the homeostasis of cerebral parenchyma by sensing neuronal activity and supporting synaptic remodeling and plasticity. While several studies demonstrated different roles for astrocytes in sleep, the contribution of microglia in the regulation of sleep/wake cycle and in the modulation of synaptic activity in the different day phases has not been deeply investigated. Using light as a zeitgeber cue, we studied the effects of microglial depletion with the colony stimulating factor-1 receptor antagonist PLX5622 on the sleep/wake cycle and on hippocampal synaptic transmission in male mice. Our data demonstrate that almost complete microglial depletion increases the duration of NREM sleep and reduces the hippocampal excitatory neurotransmission. The fractalkine receptor CX3CR1 plays a relevant role in these effects, because cx3cr1GFP/GFP mice recapitulate what found in PLX5622-treated mice. Furthermore, during the light phase, microglia express lower levels of cx3cr1 and a reduction of cx3cr1 expression is also observed when cultured microglial cells are stimulated by ATP, a purinergic molecule released during sleep. Our findings suggest that microglia participate in the regulation of sleep, adapting their cx3cr1 expression in response to the light/dark phase, and modulating synaptic activity in a phase-dependent manner.Bordeaux Region Aquitaine Initiative for Neuroscienc
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care
Introduction: This study aimed to address therapeutic inertia in the management of type 2 diabetes (T2D) by investigating the potential of early treatment with oral semaglutide. Methods: A cross-sectional survey was conducted between October 2021 and April 2022 among specialists treating individuals with T2D. A scientific committee designed a data collection form covering demographics, cardiovascular risk, glucose control metrics, ongoing therapies, and physician judgments on treatment appropriateness. Participants completed anonymous patient questionnaires reflecting routine clinical encounters. The preferred therapeutic regimen for each patient was also identified. Results: The analysis was conducted on 4449 patients initiating oral semaglutide. The population had a relatively short disease duration (42% 60% of patients, and more often than sitagliptin or empagliflozin. Conclusion: The study supports the potential of early implementation of oral semaglutide as a strategy to overcome therapeutic inertia and enhance T2D management
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer
To evaluate the impact of the Laparoscopic Approach to Cervical Cancer (LACC) Trial on patterns of care and surgery-related morbidity in early-stage cervical cancer
The role of microglial cells in modulating hippocampal synaptic plasticity and serotonergic antidepressant efficacy
An increasing number of studies show that both inflammation and neural plasticity act as key players in the
vulnerability and recovery from psychiatric disorders and neurodegenerative diseases. However, the interplay
between these two players has been limitedly explored. In fact, while a few studies reported an immune activation, others conveyed an immune suppression, associated with an impairment in neural plasticity. Therefore,
we hypothesized that deviations in inflammatory levels in both directions may impair neural plasticity. We
tested this hypothesis experimentally, by acute treatment of C57BL/6 adult male mice with different doses of
two inflammatory modulators: lipopolysaccharide (LPS), an endotoxin, and ibuprofen (IBU), a nonselective
cyclooxygenase inhibitor, which are respectively a pro- and an anti-inflammatory agent. The results showed that
LPS and IBU have different effects on behavior and inflammatory response. LPS treatment induced a reduction of
body temperature, a decrease of body weight and a reduced food and liquid intake. In addition, it led to increased levels of inflammatory markers expression, both in the total hippocampus and in isolated microglia cells,
including Interleukin (IL)-1β, and enhanced the concentration of prostaglandin E2 (PGE2). On the other hand,
IBU increased the level of anti-inflammatory markers, decreased tryptophan 2,3-dioxygenase (TDO2), the first
step in the kynurenine pathway known to be activated during inflammatory conditions, and PGE2 levels. Though
LPS and IBU administration differently affected mediators related with pro- or anti-inflammatory responses, they
produced overlapping effects on neural plasticity. Indeed, higher doses of both LPS and IBU induced a statistically significant decrease in the amplitude of long-term potentiation (LTP), in Brain-Derived Neurotrophic
Factor (BDNF) expression levels and in the phosphorylation of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor subunit GluR1, compared to the control group. Such effect appears to be dosedependent since only the higher, but not the lower, dose of both compounds led to a plasticity impairment.
Overall, the present findings indicate that acute treatment with pro- and anti-inflammatory agents impair neural
plasticity in a dose dependent manner.Although it was initially believed that the hippocampus could act in a unitary manner with properties preserved along its extension, recent evidence highlighted differences concerning physiological and functional properties along the longitudinal axis of hippocampus (Fanselow and Dong, 2010; Dougherty et al., 2012; Malik et al., 2015; Maruki et al., 2001; Maggio and Segal, 2007; Papatheodoropoulos and Kostopoulos, 2000a,b; Milior et al., 2016). In parallel, increasing evidence are emerging about the role that microglial cells play in regulating neuronal networks and functions, neuronal transmission and synaptic plasticity, supporting the existence of a close relationship between the central nervous system and the immune system (Tremblay, 2011). Here, for the first time, we examined the possible contribution of microglial cells in modulating short- and long-term plasticity in the CA1 region of dorsal and ventral hippocampus. To this purpose, we interfered with physiological functioning of microglial cells, using different approaches: i) a pharmacological depletion with PLX5622 in vivo, ii) a pharmacological inhibition with the tetracycline antibiotic minocycline in vitro, and iii) a mice model of genetic microglial deletion for CX3CR1 (fractalkine receptor) in which the microglia-neuron communication, mediated by CX3CR1 and its unique neuronal ligand CX3CL1 (fractalkine), is interrupted. In addition to having confirmed that short- and long-term plasticity are considerably different in dorsal and ventral hippocampus, we found that both minocycline and PLX5622 treatment, inverts the LTP amplitude compared to the control group in both hippocampal regions, without affecting the pre- synaptic probability of glutamate release; the same results were obtained in CX3CR1 knockout mice. Analysis of microglial distribution and morphology in the two hippocampal poles also shows significant differences, supporting our hypothesis that microglia could differently modulate neuronal functions in the dorsal and ventral hippocampus.An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in
part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable
environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel
therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our
study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a
drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful
conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To
this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse
model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine,
metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral
phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and
antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive
symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype
after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term
potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when
administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach
than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective
interventions to increase the efficacy of the antidepressant drugs currently availabl
P2X<sub>7</sub> Receptor and Extracellular Vesicle Release
Extensive evidence indicates that the activation of the P2X7 receptor (P2X7R), an ATP-gated ion channel highly expressed in immune and brain cells, is strictly associated with the release of extracellular vesicles. Through this process, P2X7R-expressing cells regulate non-classical protein secretion and transfer bioactive components to other cells, including misfolded proteins, participating in inflammatory and neurodegenerative diseases. In this review, we summarize and discuss the studies addressing the impact of P2X7R activation on extracellular vesicle release and their activities
How should I treat a patient with severe mitral regurgitation and acute decompensated heart failure?
Selecting antidepressants according to a drug-by-environment interaction: a comparison of fluoxetine and minocycline effects in mice living either in enriched or stressful conditions.
Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for major depressive disorder. It has
been recently proposed that these drugs, by enhancing neural plasticity, amplify the influences of the living
conditions on mood. Consequently, SSRI outcome depends on the quality of the environment, improving
symptomatology mainly in individuals living in favorable conditions. In adverse conditions, drugs with a
different mechanism of action might have higher efficacy. The antibiotic minocycline, with neuroprotective and
anti-inflammatory properties, has been recently proposed as a novel potential antidepressant treatment. To
explore the drug-by-environment interaction, we compared the effects on depressive-like behavior and neural
plasticity of the SSRI fluoxetine and minocycline in enriched and stressful conditions. We first exposed C57BL/6
adult female mice to 14 days of chronic unpredictable mild stress to induce a depressive-like profile. Afterward,
mice received vehicle, fluoxetine, or minocycline for 21 days, while exposed to either enriched or stressful
conditions. During the first five days, fluoxetine led to an improvement in enrichment but not in stress. By
contrast, minocycline led to an improvement in both conditions. After 21 days, all groups showed a significant
improvement in enrichment while fluoxetine worsened the depressive like behavior in stress. The effects of the
drugs on neural plasticity, measured as long-term potentiation, were also environment-dependent. Overall, we
show that the environment affects fluoxetine but not minocycline outcome, indicating that the latter represents a
potential alternative to SSRIs to treat depressed patients living in adverse conditions. From a translation
perspective, our finding call for considering the drug-by-environment interaction to select the most effective
pharmacological treatment
Combined Fluoxetine and Metformin Treatment Potentiates Antidepressant Efficacy Increasing IGF2 Expression in the Dorsal Hippocampus
An increasing number of studies show that selective serotonin reuptake inhibitors (SSRIs) exert their therapeutic action, at least in part, by amplifying the influence of the living environment on mood. As a consequence, when administered in a favorable environment, SSRIs lead to a reduction of symptoms, but in stressful conditions, they show limited efficacy. Therefore, novel therapeutic approaches able to neutralize the influence of the stressful environment on treatment are needed. The aim of our study was to test whether, in a mouse model of depression, the combined administration of SSRI fluoxetine and metformin, a drug able to improve the metabolic profile, counteracts the limited efficacy of fluoxetine alone when administered in stressful conditions. Indeed, metabolic alterations are associated to both the onset of major depression and the antidepressant efficacy. To this goal, adult C57BL/6 male mice were exposed to stress for 6 weeks; the first two weeks was aimed at generating a mouse model of depression. During the remaining 4 weeks, mice received one of the following treatments: vehicle, fluoxetine, metformin, or a combination of fluoxetine and metformin. We measured liking- and wanting-type anhedonia as behavioral phenotypes of depression and assessed the expression levels of selected genes involved in major depressive disorder and antidepressant response in the dorsal and ventral hippocampus, which are differently involved in the depressive symptomatology. The combined treatment was more effective than fluoxetine alone in ameliorating the depressive phenotype after one week of treatment. This was associated to an increase in IGF2 mRNA expression and enhanced long-term potentiation, specifically in the dorsal hippocampus, at the end of treatment. Overall, the present results show that, when administered in stressful conditions, the combined fluoxetine and metformin treatment may represent a more effective approach than fluoxetine alone in a short term. Finally, our findings highlight the relevance of polypharmacological strategy as effective interventions to increase the efficacy of the antidepressant drugs currently available
Extracellular vesicles released by microglia and macrophages carry endocannabinoids which foster oligodendrocyte differentiation
IntroductionMicroglia and macrophages can influence the evolution of myelin lesions through the production of extracellular vesicles (EVs). While microglial EVs promote in vitro differentiation of oligodendrocyte precursor cells (OPCs), whether EVs derived from macrophages aid or limit OPC maturation is unknown.MethodsImmunofluorescence analysis for the myelin protein MBP was employed to evaluate the impact of EVs from primary rat macrophages on cultured OPC differentiation. Raman spectroscopy and liquid chromatography-mass spectrometry was used to define the promyelinating lipid components of myelin EVs obtained in vitro and isolated from human plasma.Results and discussionHere we show that macrophage-derived EVs do not promote OPC differentiation, and those released from macrophages polarized towards an inflammatory state inhibit OPC maturation. However, their lipid cargo promotes OPC maturation in a similar manner to microglial EVs. We identify the promyelinating endocannabinoids anandamide and 2-arachidonoylglycerol in EVs released by both macrophages and microglia in vitro and circulating in human plasma. Analysis of OPC differentiation in the presence of the endocannabinoid receptor antagonists SR141716A and AM630 reveals a key role of vesicular endocannabinoids in OPC maturation. From this study, EV-associated endocannabinoids emerge as important mediators in microglia/macrophage-oligodendrocyte crosstalk, which may be exploited to enhance myelin repair
miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis
Cognitive deficits strongly affect the quality of life of patients with multiple sclerosis (MS). However, no cognitive MS biomarkers are currently available. Extracellular vesicles (EVs) contain markers of parental cells and are able to pass from the brain into blood, representing a source of disease biomarkers. The aim of this study was to investigate whether small non-coding microRNAs (miRNAs) targeting synaptic genes and packaged in plasma EVs may reflect cognitive deficits in MS patients. Total EVs were precipitated by Exoquick from the plasma of twenty-six cognitively preserved (CP) and twenty-three cognitively impaired (CI) MS patients belonging to two independent cohorts. Myeloid EVs were extracted by affinity capture from total EVs using Isolectin B4 (IB4). Fourteen miRNAs targeting synaptic genes were selected and measured by RT-PCR in both total and myeloid EVs. Myeloid EVs from CI patients expressed higher levels of miR-150-5p and lower levels of let-7b-5p compared to CP patients. Stratification for progressive MS (PMS) and relapsing-remitting MS (RRMS) and correlation with clinical parameters suggested that these alterations might be attributable to cognitive deficits rather than disease progression. This study identifies miR-150-5p and let-7b-5p packaged in blood myeloid EVs as possible biomarkers for cognitive deficits in MS